At a glance
ClinicalIndex Comparison Record- ✓Age ≥21 years with life expectancy ≥12 weeks
- ✓ECOG performance status 0 or 1
- ✓Histologically or cytologically confirmed Stage IA, IB, IIA, or IIB (to T2) NSCLC scheduled for surgical resection
- ✓Single measurable lesion by high-resolution CT volumetric measurement; other small indeterminate nodules may be present
- ✕Any prior anti-cancer therapy within 6 months including surgery, chemotherapy, radiation, immunotherapy, biologic therapy, or anti-angiogenic therapy
- ✕Active malignancy or any malignancy within 6 months prior to first dose
- ✕History or clinical evidence of CNS metastases or leptomeningeal carcinomatosis
- ✕Major surgical procedure, open biopsy, or significant traumatic injury within 4 weeks prior to start of therapy; minor procedures within 1 week also excluded
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Open-Label Multicenter Study to Evaluate the Safety and Efficacy of Pazopanib (GW786034) as Neoadjuvant Therapy in Treatment-Naïve Subjects With Stage IA, IB, IIA or IIB (to T2) Resectable Non-Small Cell Lung Cancer (NSCLC)
In Brief
A Phase 2 clinical trial evaluating Pazopanib for Non-Small Cell Lung Cancer and Lung Cancer, Non-Small Cell. Completed, enrolled 35 participants across 12 sites in 3 countries.
Detailed Summary
This is a phase 2 open-label, multicenter, non-randomized study to evaluate the safety and efficacy of oral pazopanib as neoadjuvant treatment for patients with stage 1A, 1B, IIA or IIB (to T2) resectable Non-Small Cell Lung Cancer (NSCLC).
Study Details
Timeline
Interventions
Pazopanib is an oral, potent, multi-target receptor tyrosine kinase inhibitor of VEGFR-1, -2, -3, PDGFR-alpha and -beta and c-kit. Subjects were to receive 800 mg oral pazopanib daily for a minimum of 2 weeks to a maximum of 6 weeks.